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Infertility affects about one in seven couples, many of whom
seek medical help to have a child.1 Although numerous new
fertility interventions and products have been developed over
the past decade, there are concerns that some might not be
evidence based and that some clinics may be offering additional
services that are not based on the most up-to-date research.2
In vitro fertilisation (IVF) is expensive—a single cycle can cost
£5000 (€5800; $6200)—and places considerable financial
burden on patients, especially as 59% of procedures are not
NHS funded.3On top of this UK fertility treatment centres offer
a range of additional investigations and treatments,4 costing
from £50 for a single screening blood test to as much as £8000
for egg freezing packages (box 1).
Guidance from the UK regulator, the Human Fertilisation and
Embryology Authority (HFEA), suggests questions that couples
might want to ask before deciding on treatment.2 These include:
Is this treatment recommended by the National Institute for
Health and Care Excellence (NICE) and, if not, why not? Has
this treatment been subjected to randomised controlled clinical
trials that show it is effective and is there a Cochrane review
available? Are there any adverse effects or risks (known or
potential) of the treatment? 2 Given concerns over the evidence
base for fertility treatments and the implications for patients we
set out to answer these questions.
What did we do?
We obtained from HFEA a list of all UK centres providing
fertility treatments and examined their websites. From these
sites we compiled a list of interventions offered in addition to
standard IVF that are claimed to improve fertility outcomes.4
We excluded interventions aimed at patients with a pre-existing
disease such as diabetes, diagnosed conditions such as polycystic
ovarian syndrome, or neurological conditions such as spinal
cord injury; we excluded interventions related to donation of
sperm or eggs; and we excluded complementary therapies such
as homeopathy and nutrition. This gave a list of 38 fertility
interventions. We classified 27 of these as add-on interventions,
six as alternatives to IVF, and five as treatments for preservation
of fertility (box 2).
For these 38 additional fertility interventions, we searched for
evidence as HFEA suggests, focusing on the key outcome of
live birth rates (see table A on thebmj.com). Nine researchers
(NB, DC, OG, KM, DN, IO, AP, ES, JOS) independently
searched Medline and the Cochrane library for systematic
reviews and randomised controlled trials in April 2016. When
we could not find any randomised controlled trials, we looked
for the next highest level of available evidence (eg, observational
study) and categorised the evidence found using the Oxford
Centre for Evidence Based Medicine levels of evidence.5 We
also searched the Cochrane reviews and NICE guidance CG156
for information on harms up to September 2016.
What did we find?
National Institute for Health and Care
Excellence recommendation
NICE provides clear advice for 13 (34%) of the 38 interventions
investigated. Of these, 11 are recommended only in specific
populations—for example, measurement of thyroid function
should be offered only to women with symptoms of thyroid
disease—and two are not recommended (hysteroscopy, assisted
hatching). There was no clear guidance for 19 interventions,
and six interventions were recommended for research only
(figure⇓).
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Box 1: Example of costs for interventions additional to standard IVF
Individual screening blood tests—start at £50
Embryoglue—up to £160
Intralipid infusions—up to £250
Endometrial scratch—up to £325
Assisted hatching—up to £450
Blastocyst culture—up to £800
Time lapse imaging—up to £850 for the Eeva time lapse incubator, up to £800 for the Embryoscope
Intracytoplasmic morphological sperm injection (IMSI)—up to £1855
Percutaneous epididymal sperm aspiration/testicular sperm extraction (PESE/ TESE)—up to £1600
Preimplantation genetic screening—£3500
Egg freezing packages—up to £8000
Box 2: Fertility interventions offered by UK centres
Add-ons (n=27)
Ovarian reserve test/ anti-mullerian hormone and antral follicle count
Thyroid antibodies
Assisted hatching
Blastocyst culture
Sperm DNA test
Hysteroscopy
Time lapse embryo imaging (including Primo vision and Embryoscope)
Endometrial scratching
Adherence compounds (Embryoglue)
Endometrial receptivity array (ERA)
AneVivo
Oral antioxidant treatment
Dummy/mock embryo transfer
Preimplantation genetic screening (PGS V1)
Preimplantation genetic screening (PGS V2) array comparative genomic hybridisation
Preimplantation genetic diagnosis (PGD)
Preimplantation genetic diagnosis for aneuploidy screening (PGD-A)
Cytokine testing (Th1, Th2) and treatment
Autoimmunity to the HCG receptor
Intralipid infusion
Embryogen
Quad therapy
Aspirin
Intracytoplasmic morphologically selected sperm injection (IMSI)
Surgical sperm retrieval
Artificial oocyte activation
SpermSlow
Alternatives (n=6)
Intrauterine insemination (IUI)
Intra-cytoplasmic sperm injection (ICSI)
Natural cycle IVF
Modified natural cycle IVF (gentle/light IVF)
Ovulation induction cycle monitoring
Segmented IVF
Preservation (n=5)
Frozen embryo transfer
Vitrification of eggs and embryos
Egg/embryo freezing
Sperm freezing
Ovarian tissue freezing
Randomised controlled clinical trials and
Cochrane reviews
For 27 of the 38 fertility interventions (71%) we found a relevant
systematic review; 18 of these were Cochrane reviews (figure⇓).
We also found one Cochrane overview, published in 2015,
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including 59 systematic reviews of the effectiveness of assisted
reproductive technologies.6 These reviews reported that five of
the 38 interventions improved live birth outcomes; for 13
interventions, the evidence was insufficient to make a summary
estimate, and for seven there was evidence that the intervention
did not improve live birth rates. For preimplantation genetic
screening older methods worsened outcomes, but there was
some evidence of benefit for more recently developed
techniques.
The five interventions for which we found evidence of
improvements in live birth rates were blastocyst culture,
endometrial scratching, adherence compounds, oral antioxidants,
and intrauterine insemination in a natural cycle. However, for
all of these interventions, the supporting studies had
methodological problems that raise uncertainty about the results
(table⇓).
We also identified one review that showed a negative effect. A
2006 Cochrane review of nine trials of preimplantation genetic
screening concluded that it significantly lowered live birth rate,12
and a 2009 review also found no benefit.13 Newer techniques
such as array comparative genomic hybridisation have
subsequently been introduced. We identified a 2015 systematic
review not done by the Cochrane group assessing four
randomised trials of the newer techniques, targeted generally
at younger women.14 In one trial delivery rates per cycle were
higher in the intervention group than the control group but in
the pooled analysis including cohort studies, there was no
significant effect. NHS England’s 2013 clinical commissioning
policy reports that in the “absence of evidence of its clinical
and cost effectiveness, there is no intention to support the
introduction of preimplantation genetic screening into NHS
clinical practice.”15
For 11 interventions we were unable to find systematic review
evidence (figure⇓). For eight of these we identified only a single
randomised trial or observational study, none of which showed
benefit. For three interventions (segmented IVF, dummy embryo
transfer, and quad therapy) we were unable to find any evidence
beyond expert opinion or mechanism of action.
Known or potential adverse effects or risks
NICE guidancewas not helpful about harms, providing comment
for only two interventions (intracytoplasmic sperm injection
(ICSI) and ovulation induction and cycle monitoring). For IVF
with or without ICSI, NICE guidance states that women should
be informed that the absolute risks of long term adverse
outcomes are low but that a small increased risk of ovarian
tumours cannot be excluded (table B on bmj.com). For ovulation
induction and cycle monitoring the guidance states the lowest
effective dose and duration of use of ovulation induction or
ovarian stimulation agents should be used—an indirect comment
on harms.
The Cochrane reviews gave limited information on harms. In
many cases the included trials provided no information,
inadequate information, or inconsistently reported information
on adverse events. For example, the review on assisted hatching
reported that miscarriage rates were similar in both groups and
multiple pregnancy rates were significantly increased in the
assisted hatching group. However, there were insufficient data
on ectopic pregnancy, congenital or chromosomal abnormalities,
blastocyst formation, or embryo damage.16
How robust is the evidence?
Of the 38 interventions we reviewed, there are only 11 for which
NICE guidance recommends use in targeted populations. Our
appraisal of the evidence shows only one intervention,
endometrial scratching, for which the review evidence robustly
supports an increase in live birth rate, yet even this evidence is
of only moderate quality, and the observed benefit is only in
women with more than two previous embryo transfers. A UK
multicentre trial is investigating the use of endometrial injury
in women undergoing IVF for the first time, which should
provide relevant information for a broader patient population.17
Cochrane systematic reviews cover less than half of the available
treatments. To find information we had to look at other reviews
or lower quality evidence, some of which is not freely available
to the public. The reporting of harms was poor and therefore
for many treatments it is impossible to be informed about
adverse effects.
There is an urgent need for randomised controlled trials for
many interventions that are currently being offered. Treatments
with uncertain effects (benefits and harms) should be licensed
for use only in the context of meaningful research. The benefits
and harms of simultaneous use of multiple interventions are
also not known.
Providing better evidence
People seeking fertility treatment need good quality evidence
to make informed choices. The current approach by HFEA
leaves patients and clinicians to seek evidence for themselves
or from staff in private clinics selling fertility services. We do
not believe this approach is realistic. Patients may be desperate,
and therefore vulnerable, and we have shown that fertility
interventions are offered without supporting evidence to back
up claims of effect.4
Patients are unlikely to have specialist skills in seeking and
critically appraising clinical evidence. For complex issues such
as genetic screening we consider the HFEA’s advice, that “you
should talk to your GP to go through the options available,”
unreasonable, as there is likely to be insufficient knowledge
available to correctly reflect the potential benefits and harms of
such interventions.2
Furthermore, there are no maintained relevant information
resources appropriate for use by non-clinicians. Initiatives such
as PubMed Health and Cochrane's plain language summaries
are welcome but they need to cover all the treatments being
offered, be updated regularly, and go beyond published papers
to overcome the reporting bias that affects much of the published
research in the fertility field.
NICE together with HFEA should provide guidance on what is
offered, and a recommendation for or against each intervention.
The framework setting out which treatments should be offered
in which populations should be clearer to reduce the potential
for indication creep, whereby use is expanded from people who
have clearly benefited to those for whom the evidence is much
more shaky or non-existent. NICE should also consider adopting
the GRADE system for making recommendations, which allows
for strong (offer to everyone) or weak (offer to certain
individuals) recommendations, with or without certain
conditions.18 Furthermore, recommendations should be based
on live birth rates rather than pregnancy rates, which are
inadequate for several reasons, not least because about 5% of
pregnancies are lost between the first trimester and birth.19
Guidance also needs continually updating if it is to be relevant
and meaningful, particularly because of the growing number of
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available tests, techniques, and treatments. Furthermore, clinics’
awareness and uptake of guidance needs improving: a recent
survey of 46 UK clinics licensed to provide intrauterine
insemination found that although most clinics were aware of
NICE guidance, only 10 clinics reduced the number of cycles
or restricted its use according to NICE recommendations.20
Currently, clinics vary widely in what they offer and there is a
lack of clarity on what constitutes an add-on intervention. Clear
classification systems and better information will aid
understanding and ensure couples enter treatment fully informed.
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Key messages
Most treatments offered by UK fertility treatment centres are not supported by good evidence
NICE provides clear advice on only 13 out 38 identified interventions, and systematic reviews were available for only 27
Information on harms is often poorly reported
Couples need clear advice on live birth rates and potential harms to make informed decisions
Table
Table 1| Interventions with systematic reviews showing evidence of improved live birth rate
Quality of evidenceEffect on live birth rate: odds ratio
(95% CI)
No of trials
(participants) in
review
High dropout rates and poor randomisation method descriptions for many
trials meant the evidence was judged low quality. Differences in live birth
rates were no longer significant (1.38 95%CI 0.96 to 1.99) after low quality
studies were removed. Variable embryo transfer policies between groups
1.48 (1.20 to 1.82) compared with culture
to day 2-3
13 (1630)Blastocyst culture7
Evidence quality was moderate because of low participant numbers and
limitations in the methods (in 5 studies both groups possibly received
some unintentional endometrial injury). Removal of the low quality studies
did not alter the effect estimate
Relative risk 1.42 (1.08 to 1.85)
compared with no injury
9 (1496)Endometrial
scratching8
In the three studies (n=324) that only assessed high versus no hyaluronic
acid there was no significant effect (OR=1.35, 95% CI 0.86 to 2.12).
Moreover, in some of the studies, multiple pregnancy rates were increased
because more embryos were transferred per woman in the intervention
groups
1.41 (1.17 to 1.69) compared with low
or no hyaluronic acid
6 (1950)Adherence
compounds9
Only 44 live births recorded. One study had inadequate methods (the
numbers of participants initially randomised to each group were not
available) and a high unexplained dropout rate (26%); in another, the
principal investigator had a commercial agreement with the manufacturer
4.21(2.08 to 8.51),4 small trials (277)Oral antioxidants10
For three other comparisons in the same review there was no significant
effect on live birth rates
1.95 (1.10 to 3.44) in one trial (n=396)
compared with intercourse or expectant
management in a stimulated cycle
14 (1867)Intrauterine
insemination in a
natural cycle11
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Figure
Evidence search for 38 interventions offered by UK fertility clinics
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